Repeated remimazolam sedation for interstitial brachytherapy in cervical cancer: a randomized controlled trial.
Ann MedOct 4, 2026 (epub)
Yanqing Wang, Handan Yang, Qian Gu et al.
✦ AI-curated · Sources linked
In 30 seconds
This randomized controlled trial evaluated the safety and efficacy of repeated remimazolam sedation compared to propofol in 100 patients with cervical cancer undergoing interstitial brachytherapy. The study found that remimazolam resulted in significantly fewer adverse events (17.78% vs 59.42%; RR, 0.30; p < 0.001) while maintaining stable sedative requirements across three sessions.
Key findings
- Remimazolam resulted in fewer overall adverse events compared to propofol (17.78% vs 59.42%; RR, 0.30; p < 0.001).
- Respiratory depression occurred less frequently with remimazolam (3.70% vs 26.09%; RR, 0.14; p = 0.004).
- Hypotension was lower in the remimazolam group (8.15% vs 41.30%; RR, 0.20; p < 0.001).
- Sedative requirements for remimazolam remained stable across sessions (mean difference, 0.19 mg; p = 0.846).
Why it matters
The findings suggest that remimazolam may be a safer alternative to propofol for sedation in patients undergoing repeated procedures, potentially reducing the risk of respiratory and hemodynamic complications.